Jacob Lalezari
Net worth: - $ as of 2026-09-29
Net worth: - $ as of 2026-09-29
Dr. Jacob P.
Lalezari was previously employed as a Chief Medical Officer by CytoDyn, Inc., a Chief Medical Officer by Virion Therapeutics LLC, a Chief Executive Officer & Medical Director by Quest Clinical Research, Inc., and a Director & Medical Director by Siempre Unidos.
He received his undergraduate degree from the University of Rochester, a graduate degree from the University of Virginia and a doctorate degree from the University of Pennsylvania.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CYTODYN INC. -.--% | 2026-03-19 | 0 ( -.--% ) | - $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| CYTODYN INC. | Chief Tech/Sci/R&D Officer | 2026-10-19 |
| Companies | Position | End |
|---|---|---|
| CYTODYN INC. | Chief Tech/Sci/R&D Officer | 2020-10-31 |
Siempre Unidos
Siempre Unidos Services to the Health IndustryHealth Services The organization provides government-authorized antiretroviral treatment following Honduran protocols, supported by advanced laboratory monitoring and US HIV specialists for complex cases. The non-profit company is located in the US. It operates HIV and primary care clinics in partnership with the Episcopal Diocese and the Honduran Ministry of Health, serving HIV-positive and HIV-negative individuals, including marginalized populations such as gay men, transgender women, commercial sex workers, Afro-Caribbean (Garifuna) people, prisoners, soldiers, women, and girls living in extreme poverty. Siempre Unidos also advocates for the rights of marginalized workers and sexual minorities, offering pro bono legal representation and monitoring violence and discrimination cases. Siempre Unidos is a nonprofit organization founded in 1999 dedicated to combating the HIV/AIDS epidemic through comprehensive medical treatment, education, and social services. | Chief Tech/Sci/R&D Officer | - |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Develops chronic viral disease vaccines | Chief Tech/Sci/R&D Officer | - |
Quest Clinical Research, Inc. | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
CytoDyn, Inc.
CytoDyn, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and commercializes pharmaceutical products to treat human immunodeficiency virus infection | Health Technology |
University of Virginia
University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Siempre Unidos
Siempre Unidos Services to the Health IndustryHealth Services The organization provides government-authorized antiretroviral treatment following Honduran protocols, supported by advanced laboratory monitoring and US HIV specialists for complex cases. The non-profit company is located in the US. It operates HIV and primary care clinics in partnership with the Episcopal Diocese and the Honduran Ministry of Health, serving HIV-positive and HIV-negative individuals, including marginalized populations such as gay men, transgender women, commercial sex workers, Afro-Caribbean (Garifuna) people, prisoners, soldiers, women, and girls living in extreme poverty. Siempre Unidos also advocates for the rights of marginalized workers and sexual minorities, offering pro bono legal representation and monitoring violence and discrimination cases. Siempre Unidos is a nonprofit organization founded in 1999 dedicated to combating the HIV/AIDS epidemic through comprehensive medical treatment, education, and social services. | Health Services |
Virion Therapeutics LLC
Virion Therapeutics LLC BiotechnologyHealth Technology Develops chronic viral disease vaccines | Health Technology |
Quest Clinical Research, Inc. |
Select your edition
All financial news and data tailored to specific country editions